Atul A Deodhar
Overview
Explore the profile of Atul A Deodhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenzweig H, Vance E, Asare-Konadu K, Koney K, Lee E, Deodhar A, et al.
Ann Rheum Dis
. 2023 Oct;
83(2):214-222.
PMID: 37813481
Objective: Polymorphisms in the antifungal signalling molecule are associated with ankylosing spondylitis (AS). Here, we investigated the cellular mechanism by which CARD9 controls pathogenic Th17 responses and the onset of...
2.
Deodhar A, Shiff N, Gong C, Hsia E, Lo K, Kim L, et al.
J Clin Rheumatol
. 2022 Jun;
28(5):270-277.
PMID: 35653615
Background/objective: This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). Methods: The phase 3,...
3.
Gladman D, Mease P, Bird P, Soriano E, Chakravarty S, Shawi M, et al.
Ann Rheum Dis
. 2022 Apr;
82(8):e187.
PMID: 35487679
No abstract available.
4.
Deodhar A, Combe B, Accioly A, Bolce R, Zhu D, Gellett A, et al.
Ann Rheum Dis
. 2022 Apr;
81(7):944-950.
PMID: 35393269
Objectives: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A (IL-17A), has shown significant efficacy in the treatment of psoriatic arthritis (PsA) and sustained long-term clinical response without unexpected...
5.
Merola J, McInnes I, Deodhar A, Dey A, Adamstein N, Quebe-Fehling E, et al.
Rheumatol Ther
. 2022 Mar;
9(3):935-955.
PMID: 35305260
Background: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are chronic immune-mediated inflammatory diseases (IMIDs) associated with cardiovascular (CV) disease. High-sensitivity C-reactive protein (hsCRP) and, more recently, the neutrophil-lymphocyte ratio...
6.
Mease P, Deodhar A, van der Heijde D, Behrens F, Kivitz A, Neal J, et al.
Ann Rheum Dis
. 2022 Mar;
81(6):815-822.
PMID: 35241426
Objective: To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods: In this double-blind, phase II...
7.
Tran K, Harrod C, Bourdette D, Cohen D, Deodhar A, Hartung D
JAMA Intern Med
. 2021 Dec;
182(2):206-217.
PMID: 34902005
Importance: Repository corticotropin injection is an expensive medication that was approved in 1952 for the treatment of many inflammatory conditions. The clinical evidence supporting the use of repository corticotropin (hereinafter...
8.
Deodhar A, Mease P, Rahman P, Navarro-Compan V, Strand V, Hunter T, et al.
BMC Rheumatol
. 2021 Sep;
5(1):35.
PMID: 34538257
Background: This analysis assessed improvements in patients with radiographic axial spondyloarthritis (r-axSpA) treated with ixekizumab in the Assessment of Spondyloarthritis International Society (ASAS) treatment response domains and additional patient-reported outcomes...
9.
Elewski B, Baddley J, Deodhar A, Magrey M, Rich P, Soriano E, et al.
JAMA Dermatol
. 2020 Oct;
157(1):43-51.
PMID: 33001147
Importance: Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually. Methotrexate, cyclosporine, and tumor necrosis factor...
10.
Deodhar A, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman D, Blanco R, et al.
ACR Open Rheumatol
. 2020 May;
2(5):294-299.
PMID: 32352653
Objective: The objective of this study was to report the incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis (AS) in a pooled analysis of three phase 3 trials (MEASURE...